reviewJournal of HepatologyMay 4, 2024Closed access

FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond

SAStephen A. HarrisonTRTim RolphMKMadeline KnottJDJulie Dubourg

John Radcliffe Hospital · University of Oxford · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

129
total citations
FWCI
27.06
Percentile
100%
References
125
Citations per year

Authors

4

Topics & keywords

Topics
Keywords
  • Steatohepatitis
  • Therapeutic window
  • Medicine
  • FGF21
  • Nonalcoholic steatohepatitis
  • Internal medicine
  • Fatty liver
  • Pharmacology
No related works found for this paper.